Reviewer’s report

Title: Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation

Version: 1 Date: 29 May 2018

Reviewer: S Saravanan

Reviewer's report:

The author has well written the manuscript, there are few queries which needs to be addressed by the author before publication

1. What is the standard of care/national guidelines for PMTCT of HBV in your country? should be discussed in discussion.
2. Is it ethical to keep HBV infected pregnant women with high viral load off therapy? if the national guideline does not insist on HBV treatment for pregnant women, the author may conclude with the statement of importance of HBV treatment for PMTCT and suggest policy makers to revise the national guideline
3. Although the treatment was stopped after delivery, Why the infant data of pregnant women who stopped Telbivudine therapy was not included?
4. What is the HBeAg status of HBsAg +ve infant's mother in Telbivudine group?
5. What is the standard of care for HBsAg +ve infants, that needs to be mentioned
6. In Results section line 180, the author has mentioned HBsAg was detected in 235 infants, it is contradictory to the next sentence.
7. Results sectionline 196-197, P=0.022, but the author has mentioned, 'no difference compared ...
8. In Introduction, line 74, log10 should be removed

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal